Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Jan 24
Show Filter
Showing of Streams
12:00pm - 12:05pm
DDP 2018 Conference Concludes

DDP 2018 Conference Concludes

8:00am - 9:00am 60 mins
Registration and Morning Coffee
8:00am - 12:00pm 240 mins
partneringONE® Meetings

You need more time for meetings with partners, customers and clients. Last year, 400+ meetings wasn't enough, so DDP 2018 will offer more than 20+ hours of partnering time through EBD Group's partneringONE®. Leverage partneringONE® to identify and qualify technology leads and close the deal that expands your product lifecycle.

9:00am - 9:15am 15 mins
Chairpersons' Remarks
  • Chairperson Ann L. Daugherty, PhD - Senior Manager, Drug Delivery, Pharmaceutical Development, Genentech Inc.
  • Chairperson Richard Korsmeyer, PhD - Drug Delivery and Innovation Expert, Korsmeyer Consulting, LLC; Pfizer (ret)
9:15am - 9:45am 30 mins
Reflections on the Future of Drug Delivery
  • Cornell Stamoran, PhD - Vice President of Corporate Strategy, Catalent Pharma Solutions

A conversation with two senior drug delivery leaders distilling key reflections on recent shifts in drug delivery, the delivery challenges patients and pipelines need us to solve most urgently, and what that means for drug delivery academics, innovators, technology providers, and future careers.

9:45am - 10:15am 30 mins
From Technology Readiness to Commercial Viability: Key Challenges in Taking New Combination Products to Market
  • Chris Hurlstone, MA - Director of Engineering, Team Consulting Limited

Based on experience gathered over twenty years of developing combination products and drug delivery devices, for companies ranging from small start-ups to multi-national organisations, the paper will describe a range of challenges typically faced, along with some strategies for over-coming them. Aspects covered will include engineering, design and human factors but also pharmaceutical, regulatory and commercial considerations.

10:15am - 10:45am 30 mins
Morning Networking Refreshment Break
10:45am - 11:30am 45 mins
Influence of Targeting Agents in Advanced Drug Delivery Systems for Pulmonary Targeting and Synthesis Characterization Strategies for Lung Cancer Nano-medicine.
  • Shraddha Ghodke - Research Scholar, UCL School of Pharmacy

“Nano-medicine” is an emerging and prominent term since last few decades which highlights up gradation of Pharmaceutical industry and formulation science. Researchers and scientists across the globe are trying to tackle problems associated with formulations pertaining to active pharmaceuticalingredient’s (API), polymers and co-polymers solubility aspects to enhance bioavailability of the selected drug at the site of action and to accentuate efficacy of desired final formulation. Nano-medicine works best with the principle of creating biomaterials and formulations (Nano-carriers) which ranges on the scale of nanometres pertaining to size parameter for efficient and advanced drug delivery.Lungs which is a mandatory constituent of human respiratory system providesextensive surface area for absorption and delivery of medicaments through airways thus assuring targeted drug delivery using targeting agents and ligandsphenomenon. Utilization of targeting agents to target receptors for localizedaction has promoted sufficient dose of the drug during delivery to the proposed disease. Targeting Lung cancer especially Non-small cell lung cancer and adenocarcinoma with anticancer agents Erlotinib, Gefitinib, Bevacizumab(Avastin), Pemetrexed, Curcumin, Paclitaxel, Carbazitaxel, Docetaxel etc. can be easily targeted on lung cancer epithelium and alveoli using CD44 andRHAMM receptor functioning. Several researchers affirm utilization of targeting moieties like Hyaluronic acid, PVA, chitosan, PLGA, PEG,hydrophobically modified polymers to boost solubility of most of the anticancer agents. Various synthetic strategies has been imposed in formulation science and Pharmaceutics for preparation of anticancer Nano-carriers which sheds light on synthetic and organic chemistry specifically conjugation reaction mechanisms. Synthesis, purification and further characterization of anti cancer agents with suitable polymers as a Nano-medicine to target Non-small cell lung cancer and metastasis via pulmonary route of administration has resolved longstanding dilemmas of chemotherapy and has attained significant phase pertaining to Drug delivery.

11:30am - 12:00pm 30 mins
Government and Industry Response to the US Opioid Epidemic
  • Robert Bianchi - President and Chief of Scientific and Technical Affairs, Prescription Drug Research Center
12:00pm - 12:05pm 5 mins
DDP 2018 Conference Concludes